|
시장보고서
상품코드
2054837
당뇨병용 의료기기 및 의약품 시장 : 카테고리별, 질환별, 지역별Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring, Therapeutics), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) |
||||||
당뇨병용 기기·의약품 시장은 2026년에 2,112억 1,000만 달러로 추계되고 있으며, 2033년까지 4,168억 5,000만 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 10.2%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 2,112억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 10.20% | 2033년 시장 규모 예측 : | 4,168억 5,000만 달러 |
당뇨병용 의료기기 및 의약품이란 고혈당을 특징으로 하는 만성 대사성 질환인 당뇨병의 관리와 치료를 지원하기 위해 특별히 설계된 기기나 약제를 말합니다. 이러한 기기와 약제는 혈당 모니터링, 인슐린 투여, 그리고 당뇨병에 수반되는 증상 및 합병증 관리에 있으며, 매우 중요한 역할을 하고 있습니다. 혈당 측정기, 연속 혈당 모니터링 시스템, 인슐린 펌프, 인슐린 펜 등은 당뇨병 관리를 돕는 기기의 일례입니다. 한편, 의약품에는 인슐린, 메트포르민, 설포닐우레아계 약물, 아밀린 유사체 등이 포함됩니다. 이러한 기기 및 의약품은 당뇨병 환자가 혈당 수치를 모니터링하고, 인슐린을 투여하며, 증상을 효과적으로 관리하는 데 필수적이며, 이를 통해 합병증의 위험을 줄이고 전반적인 건강 증진에 기여합니다.
시장 역학
전 세계 당뇨병 유병률은 주로 앉아 있는 생활 습관, 불건전한 식습관, 비만율 증가와 같은 요인으로 인해 꾸준히 증가하고 있습니다. 이러한 당뇨병 환자 수의 급증은 증상을 모니터링하고 치료하기 위한 효과적인 의료기기 및 의약품에 대한 막대한 수요를 창출하고 있습니다. 의료기기 분야에서는 연속 혈당 모니터링 시스템이 큰 인기를 끌고 있습니다. 예를 들어 2022년 3월, 당뇨병 환자를 위한 실시간 연속 혈당 모니터링 분야의 세계적 선도 기업인 DexCom, Inc.는 Dexcom G7 연속 혈당 모니터링(CGM) 시스템이 임산부를 포함한 유럽의 2세 이상 당뇨병 환자를 대상으로 CE 마크(Conformite Europeenne)를 획득했다고 발표했습니다.
당뇨병 치료제 시장에서도 눈부신 발전이 이루어지고 있습니다. 경구용 당뇨병 치료제나 인슐린 주사 같은 기존의 치료법이 여전히 시장을 독점하고 있습니다. 그러나 인크레틴계 치료제, 나트륨-글루코스 공동수송체 2(SGLT-2) 억제제, 그리고 글루카곤 유사 펩티드-1(GLP-1) 수용체 작용제를 포함한 신약 개발이 점점 더 중요시되고 있습니다. 이러한 혁신적인 약물은 효능 향상과 부작용 감소, 그리고 환자분들의 편의성 증진을 가져옵니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 당뇨병 치료용 의료기기 및 의약품 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업의 주요 정보, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략입니다.
- 이 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기종 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 이 보고서는 당뇨병 관련 의료기기 및 의약품 시장에 대해 다루고 있으며, 투자자, 공급업체, 제품 제조사, 유통업체, 신규 진입 기업, 금융 애널리스트 등 해당 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 당뇨병 의료기기 및 의약품 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 당뇨병용 의료기기·의약품 시장 : 카테고리별, 2021-2033년
제5장 세계의 당뇨병용 의료기기·의약품 시장 : 질환 유형별, 2021-2033년
제6장 세계의 당뇨병용 의료기기·의약품 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSA 26.06.18Diabetes Devices And Drugs Market is estimated to be valued at USD 211.21 Bn in 2026 and is expected to reach USD 416.85 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 211.21 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.20% | 2033 Value Projection: | USD 416.85 Bn |
Diabetes devices and drugs refer to the tools and medications specifically designed to help individuals manage and treat diabetes, a chronic metabolic disorder characterized by high blood sugar levels. These devices and drugs play a crucial role in monitoring blood glucose levels, delivering insulin, and controlling the symptoms and complications associated with diabetes. Glucose meters, continuous glucose monitoring systems, insulin pumps, insulin pens, etc. are a few examples of devices that aid the management of diabetes. Whereas, drugs include insulin, metformin, sulfonylureas, amylin analogues, etc. These devices and drugs are essential for individuals with diabetes to monitor their blood sugar levels, administer insulin, and manage the condition effectively, thereby reducing the risk of complications and promoting overall well-being.
Market Dynamics
The global prevalence of diabetes has been rising steadily primarily driven by the factors such as sedentary lifestyles, unhealthy dietary habits, and increasing obesity rates. This surge in the diabetic population has created a substantial demand for effective devices and drugs to monitor and treat the condition. In terms of devices, continuous glucose monitoring systems have gained significant popularity. For instance, in March 2022, DexCom, Inc., the global leader in real-time continuous glucose monitoring for people with diabetes, announced that the Dexcom G7 Continuous Glucose Monitoring (CGM) System received CE Mark (Conformite Europeenne) for people with diabetes in Europe aged 2 and above, including pregnant women.
The market for diabetes drugs has also witnessed remarkable advancements. Traditional treatments, such as oral antidiabetic drugs and insulin injections, continue to dominate the market. However, there has been a growing emphasis on the development of novel drugs, including incretin-based therapies, Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, and (Glucagon-like Peptide-1) GLP-1 receptor agonists. These innovative medications offer improved efficacy and reduced side effects, and enhanced convenience for patients.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetes devices and drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diabetes devices and drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetes devices and drugs market
Market Segmentation
- Global Diabetes Devices and Drugs Market, By Category (Revenue, USD Bn, 2021 - 2033)
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Other Testing Devices
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Global Diabetes Devices and Drugs Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
- Type 2 Diabetes
- Type 1 Diabetes
- Global Diabetes Devices and Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Abbott Laboratories
- Bristol-Myers Squibb
- DexCom
- Eli Lilly and Company
- Companion Medical
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Johnson & Johnson
- Lupin Ltd.
- Hoffmann-La Roche AG
- DreaMed Diabetes
- Hua Medicine
- Sanofi
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Category
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Pipeline Analysis
4. Global Diabetes Devices and Drugs Market, By Category, 2021 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Diagnosis and Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Blood Glucose Monitoring Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Other Testing Devices
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Billion)
- Segment Trends
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
5. Global Diabetes Devices and Drugs Market, By Disease Type, 2021 - 2033 (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
6. Global Diabetes Devices and Drugs Market, By Region, 2021 - 2033, (US$ Billion)
- Overview
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Category, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- DexCom, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Companion Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lupin Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- DreaMed Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hua Medicine
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
